Last updated: July 7, 2026
Roerig branded products are primarily tied to legacy Bristol Myers Squibb (BMS) heritage. In practice, the competitive landscape for “Roerig” is product-specific: each Roerig-labeled drug has its own Orange Book status, patent estate, exclusivity window, and FDA pathway. Without anchoring to a specific Roerig drug or active ingredient, an IP-accurate, expiration-ready competitive landscape cannot be produced.
No actionable patent or regulatory landscape is deliverable for “Roerig” as a standalone brand because Orange Book listings, exclusivity start/end dates, and patent claims are not indexed to the Roerig trade name in a way that supports a single, unified competitor map.
What patents protect Roerig-branded drugs and how strong is the estate?
A consolidated patent-coverage answer cannot be produced without identifying the specific Roerig active ingredient(s) and dosage forms. Patent scope and strength hinge on: (1) drug substance vs composition claims, (2) formulation/dosage form claims (including polymorphs and solid-state forms), (3) method-of-use claims, and (4) manufacturing process claims.
How do Orange Book listings map to “Roerig”?
Orange Book entries list the approved drug product by NDA/BLA and strength/route and list patents tied to that specific product. The same active ingredient can have multiple product entries with different patent sets.
What is the litigation and licensing footprint for “Roerig”?
Patent challenges and settlements (Paragraph IV ANDA litigation, biosimilar litigation under BPCIA, and 505(b)(2) disputes) occur at the NDA/BLA and patent-list level, not at the Roerig trade-name level.
When does Roerig lose exclusivity and what are the key FDA exclusivity end dates?
Exclusivity is fixed to the FDA approval event: new molecular entity (NME), new chemical entity, new clinical investigations, new formulation/exclusivity triggers, and granted exclusivities are time-bounded per application and approval date. A single “Roerig” timeline is not technically meaningful without the drug.
What exclusivity types drive launch timing for Roerig products?
- NME (5 years)
- 3-year exclusivity for certain changes
- 7-year orphan drug exclusivity (if applicable)
- Pediatric exclusivity extensions (6 months, if applicable)
- Hatch-Waxman patent term restoration (impacts effective expiration)
What is the Orange Book status of Roerig drugs: listed patents, approval route, and 180-day exclusivity risk?
Orange Book status requires the NDA number(s). Listed patents define blocking IP for ANDA applicants. 180-day exclusivity risk depends on first-filer status and eligibility tied to a particular ANDA and the challenged patent list.
Do Roerig products face Paragraph IV challenges?
Paragraph IV likelihood varies by indication, dosing frequency, dosage form complexity, and patent list size. A generic entry risk score cannot be calculated without product-level patent counts and challenge history.
How many patents cover Roerig formulations and what delivery forms are protected?
Formulation protection is product-specific: tablet vs capsule vs lyophilized vs injectables, and whether claims cover excipients, coatings, release profiles, and solid-state forms.
What formulation patents are commonly asserted in Roerig-linked product families?
Typical categories to check in the Orange Book include:
- composition of matter on specific formulation compositions
- crystal forms/polymorphs and hydrates
- sustained release and controlled release matrix claims
- unit-dose packaging or stability-related manufacturing parameters
Which companies are challenging Roerig drugs through ANDAs or biosimilars?
A credible competitor map requires:
- the NDA/BLA drug product
- the active patent(s) targeted
- the ANDA applicant(s) and corresponding litigation docket(s)
- the biosimilar sponsor(s) where BPCIA applies
How does biosimilar risk differ from generic risk for Roerig-linked products?
For biologics (BLA) the pathway is BPCIA. For small molecules (NDA) the pathway is ANDA under Hatch-Waxman. “Roerig” could include either depending on historical product mix, but a unified biosimilar risk assessment cannot be generated without drug identification.
What patent litigation affects Roerig market access and generic launch timing?
Litigation affects market entry via:
- preliminary injunctions
- final infringement findings or settlement-triggered launch dates
- “delayed 180” scenarios tied to eligibility
What settlements or consent decrees block or delay entry?
Settlement terms are determined per asserted patent and per NDA. Without a specific Roerig drug, settlement timing and “at-risk” launch windows cannot be mapped.
How does Roerig compare with current branded competitors in the same therapeutic class?
Comparative positioning is also drug-specific. Roerig can map to multiple therapeutic areas across BMS history. Competitive pressure depends on:
- presence of direct generics
- line extensions and lifecycle management
- payer formularies and rebate dynamics (often indication- and plan-specific)
What metrics should be used to benchmark Roerig vs peers?
For each active ingredient/drug product:
- net sales by dosage form (company reporting)
- market share and realized price trends
- PBM rebate position and formulary tiering
- competitor launch dates (generic and authorized generic)
What generic entry risks exist for Roerig products under at-risk launch scenarios?
“At-risk” entry requires:
- patent expiration/PSA schedules
- Orange Book list blocking strength
- litigation posture (including stays)
- ANDA approval status (tentative vs final)
- label carve-outs (if relevant)
How do patent strength and remaining term change generic probability?
Generic probability is a function of:
- remaining patent term on the specific claims
- whether key claims are “weak” (e.g., obviousness vulnerabilities) or “hard” (e.g., late-issued composition claims with long term)
- whether the patent set is redundant or dominated by a few high-impact patents
Which geographies matter for Roerig’s competitive landscape: US exclusivity vs EU/UK vs emerging markets?
Exclusivity and patent term are jurisdictional:
- US: Orange Book patents + FDA exclusivity
- EU/UK: SPCs (Supplementary Protection Certificates) and national patent enforcement
- emerging markets: local patentability, enforcement intensity, and regulatory filing practices
How do SPCs and local filings affect Roerig launch timing in Europe?
European timing requires:
- corresponding EP family coverage
- SPC registration status
- national marketing authorization status and reference product conditions
Key takeaways
- “Roerig” is a brand label, not a single regulatory product. A defensible competitive landscape requires the specific Roerig active ingredient(s) and corresponding NDA/BLA product(s).
- Patent coverage, exclusivity end dates, Orange Book status, litigation risk, and generic/biosimilar launch probability are determined at the NDA/BLA and patent-list level, not at the trade-name level.
- Without product-level anchoring, any attempt to provide expiration timelines, patent counts, or competitor/Paragraph IV maps would be non-actionable.
FAQs
- How do I identify the exact NDA/BLA for a Roerig-labeled drug to build an Orange Book patent map?
- What patents usually block ANDA applicants for products with Roerig-branded labeling: formulation, method-of-use, or drug substance claims?
- How do pediatric exclusivity and patent term adjustments change US launch timing for Roerig-linked products?
- What is the difference between at-risk generic launch timing and settlement-triggered launch timing for Roerig products?
- How do EU SPC registrations alter competitive timing compared with US Orange Book and FDA exclusivity?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-07). https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. FDA. Exclusivity and Patent/Orphan Drug Considerations. (Accessed 2026-07-07). https://www.fda.gov/drugs/
- FDA. Drugs@FDA (Drug product records). (Accessed 2026-07-07). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
